Poniard Pharmaceuticals, Inc. (PARD)

Poniard Pharmaceuticals, Inc., together with its subsidiary, NeoRx Manufacturing Group, Inc., focuses on the development and commercialization of oncology products for people with cancer. Its lead platform product candidate, Picoplatin, is a platinum-based cancer therapy that is designed to overcome platinum resistance associated with chemotherapy in solid tumors. Picoplatin is being studied in various cancer indications, combinations, and formulations. Poniard Pharmaceuticals is conducting a phase III clinical trial of intravenous picoplatin in small cell lung cancer; two phase II clinical trials in metastatic colorectal and castration-resistant (hormone refractory) prostate cancers; and a clinical trial of oral picoplatin in solid tumors. The company was formerly known as NeoRx Corporation and changed its name to Poniard Pharmaceuticals Inc. in June 2006. Poniard Pharmaceuticals was founded in 1984 and is headquartered in South San Francisco, California.

For the six months ended 30 June 2006, Poniard Pharmaceuticals, Inc.'s revenues totaled $0, down from $2K. Net loss applic. to Common fell 12% to $12.5M. Revenues reflect the Company not generating any revenues due to the non commercialization of product. Lower loss reflects the absence of asset impairment loss, the absence of restructuring charges, an increase in interest income and the presence of gain on sale of equipment.